HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

Documenti analoghi

• The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants
  di: Volk, Jonathan E., et al.
  Pubblicazione: (2013)
• Self-reported Benefits of Study Participation in HVTN 503, “Phambili”
  di: Allen, Mary A., et al.
  Pubblicazione: (2014)
• Pregnancy Incidence and Correlates during the HVTN 503 Phambili HIV Vaccine Trial Conducted among South African Women
  di: Latka, Mary H., et al.
  Pubblicazione: (2012)
• P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
  di: Gray, GE, et al.
  Pubblicazione: (2009)
• P15-13. HVTN 503(Phambili) trial discontinuation of enrolment/vaccination: the impact on trial participant attitudes to vaccine trials and scientific research
  di: Mark, D, et al.
  Pubblicazione: (2009)